AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer

AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer

Submitted by admin on July 19, 2021 - 11:05am
Source: 
Endpoints
News Tags: 
AstraZeneca
China
Imfinzi
Headline: 
AstraZeneca earns another approval in jam-packed Chinese PD-(L)1 market, this time in late-stage lung cancer
snippet: 

One of the first entrants in the PD-(L)1 market in China, British drugmaker AstraZeneca is now looking to cement its advantage there with another approval for checkpoint inhibitor Imfinzi.

Do Not Allow Advertisers to Use My Personal information